Perhaps. However, it is a 400 million dollar plate......so should the stock be worth more than .28 soon? My bet is yes, a whole lot more. "Under the expected terms of the deal, Statera will receive an initial $2 million upfront payment and 5% of the issued and outstanding stock of Immune Therapeutics. Statera will also receive payments for, among other things, achievement of revenue-based milestones, new indications and royalties, in exchange for its rights to any product containing low-dose naltrexone as an active ingredient, the companies said.
In aggregate, the deal could generate over $400 million in non-dilutive payments to Statera, the company said."
Just saying....
News 
Market Data 
Discover 
